



References

Abate-Shen C, Shen MM. 2000. Molecular genetics of prostate

cancer. Genes Dev 14: 2410–2434.

Abate-Shen C, Banach-Petrosky WA, Sun X, Economides KD,

Desai N, Gregg JP, Borowsky AD, Cardiff RD, Shen MM.

2003. Nkx3.1; Pten mutant mice develop invasive prostate

adenocarcinoma and lymph node metastases. Cancer Res 63:

3886–3890.

Abate-Shen C, Shen MM, Gelmann E. 2008. Integrating differentiation and cancer: The Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Differentiation 76:

717–727.

Abdulkadir SA, Magee JA, Peters TJ, Kaleem Z, Naughton CK,

Humphrey PA, Milbrandt J. 2002. Conditional loss of Nkx3.1

in adult mice induces prostatic intraepithelial neoplasia. Mol

Cell Biol 22: 1495–1503.

Abreu-Martin MT, Chari A, Palladino AA, Craft NA, Sawyers

CL. 1999. Mitogen-activated protein kinase kinase kinase 1

activates androgen receptor-dependent transcription and

apoptosis in prostate cancer. Mol Cell Biol 19: 5143–5154.

Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F,

Ayala GE, Peterson LE, Ittmann M, Spencer DM. 2007.

Inducible FGFR-1 activation leads to irreversible prostate

adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 12: 559–571.

Adams JM, Strasser A. 2008. Is tumor growth sustained by rare

cancer stem cells or dominant clones? Cancer Res 68: 4018–

4021.

Adam RM, Mukhopadhyay NK, Kim J, Di Vizio D, Cinar B,

Boucher K, Solomon KR, Freeman MR. 2007. Cholesterol

sensitivity of endogenous and myristoylated Akt. Cancer

Res 67: 6238–6246.




Agoulnik IU, Vaid A, Bingman WE III, Erdeme H, Frolov A,

Smith CL, Ayala G, Ittmann MM, Weigel NL. 2005. Role of

SRC-1 in the promotion of prostate cancer cell growth and

tumor progression. Cancer Res 65: 7959–7967.

Aihara M, Wheeler TM, Ohori M, Scardino PT. 1994. Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology 43: 60–66.

Albadine R, Latour M, Toubaji A, Haffner M, Isaacs WB, Platz

EA, Meeker AK, Demarzo AM, Epstein JI, Netto GJ 2009.

TMPRSS2-ERG gene fusion status in minute (minimal)

prostatic adenocarcinoma. Mod Pathol 22: 1415–1422.

Albertsen PC, Hanley JA, Fine J. 2005. 20-year outcomes

following conservative management of clinically localized

prostate cancer. JAMA 293: 2095–2101.

Alimonti A, Nardella C, Chen Z, Clohessy JG, Carracedo A,

Trotman LC, Cheng K, Varmeh S, Kozma SC, Thomas G,

et al. 2010. A novel type of cellular senescence that can be

enhanced in mouse models and human tumor xenografts

to suppress prostate tumorigenesis. J Clin Invest 120:

681–693.

Al Olama AA, Kote-Jarai Z, Giles GG, Guy M, Morrison J,

Severi G, Leongamornlert DA, Tymrakiewicz M, Jhavar S,

Saunders E, et al. 2009. Multiple loci on 8q24 associated with

prostate cancer susceptibility. Nat Genet 41: 1058–1060.

Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F,

Wallace TA, Liu CG, Volinia S, Calin GA, et al. 2008.

Genomic profiling of microRNA and messenger RNA reveals

deregulated microRNA expression in prostate cancer. Cancer Res 68: 6162–6170.

American_Cancer_Society. 2009. Cancer facts & figures 2009.

American Cancer Society, Atlanta, GA.

Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker

A, Agnarsson BA, Sigurdsson A, Benediktsdottir KR, Cazier

JB, Sainz J, et al. 2006. A common variant associated with

prostate cancer in European and African populations. Nat

Genet 38: 652–658.

Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK,

Watt K, Tam T, Yang YC, Banuelos CA, et al. 2010. Regression of castrate-recurrent prostate cancer by a smallmolecule inhibitor of the amino-terminus domain of the

androgen receptor. Cancer Cell 17: 535–546.

Asai A, Oshima Y, Yamamoto Y, Uochi TA, Kusaka H, Akinaga

S, Yamashita Y, Pongracz K, Pruzan R, Wunder E, et al. 2003.

A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res 63: 3931–3939.

Asatiani E, Huang WX, Wang A, Rodriguez Ortner E, Cavalli LR,

Haddad BR, Gelmann EP. 2005. Deletion, methylation, and

expression of the NKX3.1 suppressor gene in primary human

prostate cancer. Cancer Res 65: 1164–1173.

Attar RM, Takimoto CH, Gottardis MM. 2009. Castrationresistant prostate cancer: Locking up the molecular escape

routes. Clin Cancer Res 15: 3251–3255.

Attard G, Cooper CS, de Bono JS. 2009a. Steroid hormone

receptors in prostate cancer: A hard habit to break? Cancer

Cell 16: 458–462.

Attard G, Reid AH, Olmos D, de Bono JS. 2009b. Antitumor

activity with CYP17 blockade indicates that castrationresistant prostate cancer frequently remains hormone driven.

Cancer Res 69: 4937–4940.

Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A’Hern

R, Levink R, Coumans F, Moreira J, Riisnaes R, et al. 2009c.

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant

prostate cancer. Cancer Res 69: 2912–2918.

Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume

O, Haukaas SA, Salvesen HB, Otte AP, Akslen LA. 2006.




GENES & DEVELOPMENT




1987




Shen and Abate-Shen




EZH2 expression is associated with high proliferation rate

and aggressive tumor subgroups in cutaneous melanoma and

cancers of the endometrium, prostate, and breast. J Clin

Oncol 24: 268–273.

Bai F, Pei XH, Pandolfi PP, Xiong Y. 2006. p18 Ink4c and Pten

constrain a positive regulatory loop between cell growth and

cell cycle control. Mol Cell Biol 26: 4564–4576.

Banach-Petrosky W, Ouyang X, Gao H, Nader K, Ji Y, Suh N,

DiPaola RS, Abate-Shen C. 2006. Vitamin D inhibits the

formation of prostatic intraepithelial neoplasia in Nkx3.1;Pten

mutant mice. Clin Cancer Res 12: 5895–5901.

Banach-Petrosky W, Jessen WJ, Ouyang X, Gao H, Rao J, Quinn

J, Aronow BJ, Abate-Shen C. 2007. Prolonged exposure to

reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice. Cancer Res 67: 9089–

9096.

Bardia A, Platz EA, Yegnasubramanian S, De Marzo AM, Nelson

WG. 2009. Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. Curr Opin Pharmacol 9: 419–426.

Bavik C, Coleman I, Dean JP, Knudsen B, Plymate S, Nelson PS.

2006. The gene expression program of prostate fibroblast

senescence modulates neoplastic epithelial cell proliferation

through paracrine mechanisms. Cancer Res 66: 794–802.

Begley L, Monteleon C, Shah RB, Macdonald JW, Macoska JA.

2005. CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in

vitro. Aging Cell 4: 291–298.

Bergerat JP, Ceraline J. 2009. Pleiotropic functional properties of

androgen receptor mutants in prostate cancer. Hum Mutat

30: 145–157.

Berman DM, Desai N, Wang X, Karhadkar SS, Reynon M, AbateShen C, Beachy PA, Shen MM. 2004. Roles for Hedgehog

signaling in androgen production and prostate ductal morphogenesis. Dev Biol 267: 387–398.

Berquin IM, Min Y, Wu R, Wu H, Chen YQ. 2005. Expression

signature of the mouse prostate. J Biol Chem 280: 36442–

36451.

Berquin IM, Min Y, Wu R, Wu J, Perry D, Cline JM, Thomas MJ,

Thornburg T, Kulik G, Smith A, et al. 2007. Modulation of

prostate cancer genetic risk by omega-3 and omega-6 fatty

acids. J Clin Invest 117: 1866–1875.

Berruti A, Mosca A, Porpiglia F, Bollito E, Tucci M, Vana F,

Cracco C, Torta M, Russo L, Cappia S, et al. 2007. Chromogranin A expression in patients with hormone naive

prostate cancer predicts the development of hormone refractory disease. J Urol 178: 838–843, quiz 1129.

Bertram J, Peacock JW, Fazli L, Mui AL, Chung SW, Cox ME,

Monia B, Gleave ME, Ong CJ. 2006. Loss of PTEN is

associated with progression to androgen independence. Prostate 66: 895–902.

Bethel CR, Faith D, Li X, Guan B, Hicks JL, Lan F, Jenkins RB,

Bieberich CJ, De Marzo AM. 2006. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: Association with

gleason score and chromosome 8p deletion. Cancer Res 66:

10683–10690.

Bethel CR, Chaudhary J, Anway MD, Brown TR. 2009. Gene

expression changes are age-dependent and lobe-specific in

the brown Norway rat model of prostatic hyperplasia.

Prostate 69: 838–850.

Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, Kim M, Desai N,

Young P, Norton CR, Gridley T, Cardiff RD, Cunha GR, et al.

1999. Roles for Nkx3.1 in prostate development and cancer.

Genes Dev 13: 966–977.

Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N,

Shappell S, Washington MK, Neilson EG, Moses HL. 2004.




1988




GENES & DEVELOPMENT




TGF-b signaling in fibroblasts modulates the oncogenic

potential of adjacent epithelia. Science 303: 848–851.

Birbach A, Casanova E, Schmid JA. 2009. A Probasin-MerCreMer

BAC allows inducible recombination in the mouse prostate.

Genesis 47: 757–764.

Birnie R, Bryce SD, Roome C, Dussupt V, Droop A, Lang SH,

Berry PA, Hyde CF, Lewis JL, Stower MJ, et al. 2008. Gene

expression profiling of human prostate cancer stem cells

reveals a pro-inflammatory phenotype and the importance of

extracellular matrix interactions. Genome Biol 9: R83. doi:

10.1186/gb-2008-9-5-r83.

Blum DL, Koyama T, M’Koma AE, Iturregui JM, Martinez-Ferrer

M, Uwamariya C, Smith JA Jr, Clark PE, Bhowmick NA.

2008. Chemokine markers predict biochemical recurrence of

prostate cancer following prostatectomy. Clin Cancer Res

14: 7790–7797.

Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo

L, D’Urso L, Pagliuca A, Biffoni M, Labbaye C, et al. 2008. The

miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 14: 1271–1277.

Bonkhoff H, Berges R. 2010. From pathogenesis to prevention of

castration resistant prostate cancer. Prostate 70: 100–112.

Boormans JL, Hermans KG, van Leenders GJ, Trapman J,

Verhagen PC. 2008. An activating mutation in AKT1 in

human prostate cancer. Int J Cancer 123: 2725–2726.

Borowsky AD, Dingley KH, Ubick E, Turteltaub KW, Cardiff

RD, Devere-White R. 2006. Inflammation and atrophy precede prostatic neoplasia in a PhIP-induced rat model. Neoplasia 8: 708–715.

Bostwick DG. 1989. Prostatic intraepithelial neoplasia (PIN).

Urology 34: 16–22.

Bostwick DG, Shan A, Qian J, Darson M, Maihle NJ, Jenkins RB,

Cheng L. 1998. Independent origin of multiple foci of prostatic intraepithelial neoplasia: Comparison with matched

foci of prostate carcinoma. Cancer 83: 1995–2002.

Bostwick DG, Alexander EE, Singh R, Shan A, Qian J, Santella

RM, Oberley LW, Yan T, Zhong W, Jiang X, et al. 2000.

Antioxidant enzyme expression and reactive oxygen species

damage in prostatic intraepithelial neoplasia and cancer.

Cancer 89: 123–134.

Bowen C, Gelmann EP. 2010. NKX3.1 activates cellular response to DNA damage. Cancer Res 70: 3089–3097.

Bowen C, Bubendorf L, Voeller HJ, Slack R, Willi N, Sauter G,

Gasser TC, Koivisto P, Lack EE, Kononen J, et al. 2000. Loss

of NKX3.1 expression in human prostate cancers correlates

with tumor progression. Cancer Res 60: 6111–6115.

Brooke GN, Parker MG, Bevan CL. 2008. Mechanisms of

androgen receptor activation in advanced prostate cancer:

Differential co-activator recruitment and gene expression.

Oncogene 27: 2941–2950.

Bruxvoort KJ, Charbonneau HM, Giambernardi TA, Goolsby JC,

Qian CN, Zylstra CR, Robinson DR, Roy-Burman P, Shaw

AK, Buckner-Berghuis BD, et al. 2007. Inactivation of Apc in

the mouse prostate causes prostate carcinoma. Cancer Res

67: 2490–2496.

Bryant RJ, Winder SJ, Cross SS, Hamdy FC, Cunliffe VT. 2008.

The Polycomb Group protein EZH2 regulates actin polymerization in human prostate cancer cells. Prostate 68: 255–263.

Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N,

Gasser TC, Mihatsch MJ. 2000. Metastatic patterns of

prostate cancer: An autopsy study of 1,589 patients. Hum

Pathol 31: 578–583.

Burger PE, Xiong X, Coetzee S, Salm SN, Moscatelli D, Goto K,

Wilson EL. 2005. Sca-1 expression identifies stem cells in the

proximal region of prostatic ducts with high capacity to reconstitute prostatic tissue. Proc Natl Acad Sci 102: 7180–7185.




Molecular genetics of prostate cancer




Calabro F, Sternberg CN. 2007. Current indications for chemotherapy in prostate cancer patients. Eur Urol 51: 17–26.

Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA,

Mehra R, Laxman B, Cao X, Kleer CG, et al. 2008. Repression

of E-cadherin by the polycomb group protein EZH2 in

cancer. Oncogene 27: 7274–7284.

Capasso LL. 2005. Antiquity of cancer. Int J Cancer 113: 2–13.

Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J,

Faruque M, Moses T, Ewing C, Gillanders E, et al. 2002.

Germline mutations in the ribonuclease L gene in families

showing linkage with HPC1. Nat Genet 30: 181–184.

Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY,

Sulman EP, Anne SL, Doetsch F, Colman H, et al. 2009. The

transcriptional network for mesenchymal transformation of

brain tumours. Nature 463: 318–325.

Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A,

Alimonti A, Nardella C, Varmeh S, Scardino PT, et al. 2009.

Aberrant ERG expression cooperates with loss of PTEN to

promote cancer progression in the prostate. Nat Genet 41:

619–624.

Casey G, Neville PJ, Plummer SJ, Xiang Y, Krumroy LM, Klein

EA, Catalona WJ, Nupponen N, Carpten JD, Trent JM, et al.

2002. RNASEL Arg462Gln variant is implicated in up to

13% of prostate cancer cases. Nat Genet 32: 581–583.

Castro P, Giri D, Lamb D, Ittmann M. 2003. Cellular senescence

in the pathogenesis of benign prostatic hyperplasia. Prostate

55: 30–38.

Chen L, Stacewicz-Sapuntzakis M, Duncan C, Sharifi R, Ghosh

L, van Breemen R, Ashton D, Bowen PE. 2001. Oxidative

DNA damage in prostate cancer patients consuming tomato

sauce-based entrees as a whole-food intervention. J Natl

Cancer Inst 93: 1872–1879.

Chen Z, Koeneman KS, Corey DR. 2003. Consequences of

telomerase inhibition and combination treatments for the

proliferation of cancer cells. Cancer Res 63: 5917–5925.

Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R,

Rosenfeld MG, Sawyers CL. 2004. Molecular determinants

of resistance to antiandrogen therapy. Nat Med 10: 33–39.

Chen H, Tu SW, Hsieh JT. 2005. Down-regulation of human

DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem

280: 22437–22444.

Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M,

Koutcher JA, Scher HI, Ludwig T, Gerald W, et al. 2005.

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436: 725–730.

Chen L, Ambrosone CB, Lee J, Sellers TA, Pow-Sang J, Park JY.

2006. Association between polymorphisms in the DNA

repair genes XRCC1 and APE1, and the risk of prostate

cancer in white and black Americans. J Urol 175: 108–112.

Chen ML, Xu PZ, Peng XD, Chen WS, Guzman G, Yang X, Di

Cristofano A, Pandolfi PP, Hay N. 2006. The deficiency of

Akt1 is sufficient to suppress tumor development in Pten+/!

mice. Genes Dev 20: 1569–1574.

Chen Y, Clegg NJ, Scher HI. 2009. Anti-androgens and androgendepleting therapies in prostate cancer: New agents for an

established target. Lancet Oncol 10: 981–991.

Chen Z, Carracedo A, Lin HK, Koutcher JA, Behrendt N, Egia A,

Alimonti A, Carver BS, Gerald W, Teruya-Feldstein J, et al.

2009. Differential p53-independent outcomes of p19(Arf) loss

in oncogenesis. Sci Signal 2: ra44. doi: 10.1126/scisignal.

2000053.

Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N,

Shen Q, O’Hagan R, Pantginis J, Zhou H, et al. 1999.

Essential role for oncogenic Ras in tumour maintenance.

Nature 400: 468–472.




Chiosea S, Jelezcova E, Chandran U, Acquafondata M, McHale T,

Sobol RW, Dhir R. 2006. Up-regulation of dicer, a component

of the microRNA machinery, in prostate adenocarcinoma. Am

J Pathol 169: 1812–1820.

Choi J, Shendrik I, Peacocke M, Peehl D, Buttyan R, Ikeguchi EF,

Katz AE, Benson MC. 2000. Expression of senescenceassociated b-galactosidase in enlarged prostates from men

with benign prostatic hyperplasia. Urology 56: 160–166.

Clark J, Merson S, Jhavar S, Flohr P, Edwards S, Foster CS, Eeles

R, Martin FL, Phillips DH, Crundwell M, et al. 2007.

Diversity of TMPRSS2-ERG fusion transcripts in the human

prostate. Oncogene 26: 2667–2673.

Clark J, Attard G, Jhavar S, Flohr P, Reid A, De-Bono J, Eeles R,

Scardino P, Cuzick J, Fisher G, et al. 2008. Complex patterns

of ETS gene alteration arise during cancer development in

the human prostate. Oncogene 27: 1993–2003.

Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. 2005.

Prospective identification of tumorigenic prostate cancer

stem cells. Cancer Res 65: 10946–10951.

Coppola V, De Maria R, Bonci D. 2009. MicroRNAs and prostate

cancer. Endocr Relat Cancer 17: F1–F17. doi: 10.1677/ERC09-0172.

Cordon-Cardo C, Kotsianti A, Verbel DA, Teverovskiy M,

Capodieci P, Hamann S, Jeffers Y, Clayton M, Elkhettabi F,

Khan FM, et al. 2007. Improved prediction of prostate cancer

recurrence through systems pathology. J Clin Invest 117:

1876–1883.

Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM,

Buhler KR, Vessella RL. 2002. Establishment and characterization of osseous prostate cancer models: Intra-tibial injection of human prostate cancer cells. Prostate 52: 20–33.

Courtois-Cox S, Jones SL, Cichowski K. 2008. Many roads lead

to oncogene-induced senescence. Oncogene 27: 2801–2809.

Craft N, Chhor C, Tran C, Belldegrun A, DeKernion J, Witte

ON, Said J, Reiter RE, Sawyers CL. 1999a. Evidence for

clonal outgrowth of androgen-independent prostate cancer

cells from androgen-dependent tumors through a two-step

process. Cancer Res 59: 5030–5036.

Craft N, Shostak Y, Carey M, Sawyers CL. 1999b. A mechanism

for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5: 280–285.

Cunha GR. 2008. Mesenchymal–epithelial interactions: Past,

present, and future. Differentiation 76: 578–586.

Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM,

Higgins SJ, Sugimura Y. 1987. The endocrinology and developmental biology of the prostate. Endocr Rev 8: 338–362.

d’Adda di Fagagna F. 2008. Living on a break: Cellular senescence

as a DNA-damage response. Nat Rev Cancer 8: 512–522.

Dakhova O, Ozen M, Creighton CJ, Li R, Ayala G, Rowley D,

Ittmann M. 2009. Global gene expression analysis of reactive

stroma in prostate cancer. Clin Cancer Res 15: 3979–3989.

Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JP, Baldwin

AS. 2008. Akt-dependent regulation of NF-kB is controlled

by mTOR and Raptor in association with IKK. Genes & Dev

22: 1490–1500.

Deeb KK, Trump DL, Johnson CS. 2007. Vitamin D signalling

pathways in cancer: Potential for anticancer therapeutics.

Nat Rev Cancer 7: 684–700.

Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ.

2008. Splicing of a novel androgen receptor exon generates

a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68: 5469–5477.

De Marzo AM, Marchi VL, Epstein JI, Nelson WG. 1999. Proliferative inflammatory atrophy of the prostate: Implications

for prostatic carcinogenesis. Am J Pathol 155: 1985–1992.




GENES & DEVELOPMENT




1989




Shen and Abate-Shen




De Marzo AM, Meeker AK, Zha S, Luo J, Nakayama M, Platz

EA, Isaacs WB, Nelson WG. 2003. Human prostate cancer

precursors and pathobiology. Urology 62: 55–62.

De Marzo AM, Nakai Y, Nelson WG. 2007a. Inflammation,

atrophy, and prostate carcinogenesis. Urol Oncol 25: 398–

400.

De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake

CG, Nakai Y, Isaacs WB, Nelson WG. 2007b. Inflammation

in prostate carcinogenesis. Nat Rev Cancer 7: 256–269.

DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. 2003. Pathological and molecular aspects of prostate cancer. Lancet 361:

955–964.

DeVere White RW, Vinall RL, Tepper CG, Shi XB. 2009. MicroRNAs and their potential for translation in prostate cancer.

Urol Oncol 27: 307–311.

DeWeese TL, Hruszkewycz AM, Marnett LJ. 2001. Oxidative

stress in chemoprevention trials. Urology 57: 137–140.

Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. 1998a.

Pten is essential for embryonic development and tumour

suppression. Nat Genet 19: 348–355.

Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. 1998b.

Pten is essential for embryonic development and tumour

suppression. Nat Genet 19: 348–355.

Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi

PP. 2001. Pten and p27KIP1 cooperate in prostate cancer

tumor suppression in the mouse. Nat Genet 27: 222–224.

Doles J, Cook C, Shi X, Valosky J, Lipinski R, Bushman W. 2006.

Functional compensation in Hedgehog signaling during

mouse prostate development. Dev Biol 295: 13–25.

Dong JT. 2001. Chromosomal deletions and tumor suppressor

genes in prostate cancer. Cancer Metastasis Rev 20: 173–193.

Dong B, Kim S, Hong S, Das Gupta J, Malathi K, Klein EA,

Ganem D, Derisi JL, Chow SA, Silverman RH. 2007. An

infectious retrovirus susceptible to an IFN antiviral pathway

from human prostate tumors. Proc Natl Acad Sci 104: 1655–

1660.

Donjacour AA, Thomson AA, Cunha GR. 2003. FGF-10 plays an

essential role in the growth of the fetal prostate. Dev Biol

261: 39–54.

Dunn JE. 1975. Cancer epidemiology in populations of the

United States—with emphasis on Hawaii and California—and Japan. Cancer Res 35: 3240–3245.

Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi

G, Muir K, Hopper JL, Henderson BE, Haiman CA, et al.

2009. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat

Genet 41: 1116–1121.

Eggener SE, Scardino PT, Carroll PR, Zelefsky MJ, Sartor O,

Hricak H, Wheeler TM, Fine SW, Trachtenberg J, Rubin MA,

et al. 2007. Focal therapy for localized prostate cancer: A

critical appraisal of rationale and modalities. J Urol 178:

2260–2267.

Elkahwaji JE, Zhong W, Hopkins WJ, Bushman W. 2007. Chronic

bacterial infection and inflammation incite reactive hyperplasia in a mouse model of chronic prostatitis. Prostate 67:

14–21.

Elkahwaji JE, Hauke RJ, Brawner CM. 2009. Chronic bacterial

inflammation induces prostatic intraepithelial neoplasia in

mouse prostate. Br J Cancer 101: 1740–1748.

Ellis WJ, Vessella RL, Buhler KR, Bladou F, True LD, Bigler SA,

Curtis D, Lange PH. 1996. Characterization of a novel

androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res 2:

1039–1048.

Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML,

Zhang J, Matusik R, Thomas GV, Sawyers CL. 2003. Myc-




1990




GENES & DEVELOPMENT




driven murine prostate cancer shares molecular features

with human prostate tumors. Cancer Cell 4: 223–238.

Emmert-Buck MR, Vocke CD, Pozzatti RO, Duray PH, Jennings

SB, Florence CD, Zhuang Z, Bostwick DG, Liotta LA, Linehan

WM. 1995. Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res 55:

2959–2962.

English HF, Santen RJ, Isaacs JT. 1987. Response of glandular

versus basal rat ventral prostatic epithelial cells to androgen

withdrawal and replacement. Prostate 11: 229–242.

Epstein JI. 2010. An update of the Gleason grading system.

J Urol 183: 433–440.

Evan GI, d’Adda di Fagagna F. 2009. Cellular senescence: Hot or

what? Curr Opin Genet Dev 19: 25–31.

Evans GS, Chandler JA. 1987. Cell proliferation studies in the

rat prostate: II. The effects of castration and androgeninduced regeneration upon basal and secretory cell proliferation. Prostate 11: 339–351.

Fizazi K. 2007. The role of Src in prostate cancer. Ann Oncol 18:

1765–1773.

Fordyce CA, Heaphy CM, Joste NE, Smith AY, Hunt WC,

Griffith JK. 2005. Association between cancer-free survival

and telomere DNA content in prostate tumors. J Urol 173:

610–614.

Foster BA, Evangelou A, Gingrich JR, Kaplan PJ, DeMayo F,

Greenberg NM. 2002. Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative

FGFR2iiib promotes the emergence of neuroendocrine phenotype in prostate glands of transgenic mice. Differentiation

70: 624–632.

Foster CS, Dodson A, Karavana V, Smith PH, Ke Y. 2002.

Prostatic stem cells. J Pathol 197: 551–565.

Fradet V, Lessard L, Begin LR, Karakiewicz P, Masson AM, Saad

F. 2004. Nuclear factor-kB nuclear localization is predictive

of biochemical recurrence in patients with positive margin

prostate cancer. Clin Cancer Res 10: 8460–8464.

Freedman ML, Haiman CA, Patterson N, McDonald GJ, Tandon

A, Waliszewska A, Penney K, Steen RG, Ardlie K, John EM,

et al. 2006. Admixture mapping identifies 8q24 as a prostate

cancer risk locus in African-American men. Proc Natl Acad

Sci 103: 14068–14073.

Freeman KW, Gangula RD, Welm BE, Ozen M, Foster BA, Rosen

JM, Ittmann M, Greenberg NM, Spencer DM. 2003. Conditional activation of fibroblast growth factor receptor (FGFR) 1,

but not FGFR2, in prostate cancer cells leads to increased

osteopontin induction, extracellular signal-regulated kinase

activation, and in vivo proliferation. Cancer Res 63: 6237–6243.

Freestone SH, Marker P, Grace OC, Tomlinson DC, Cunha GR,

Harnden P, Thomson AA. 2003. Sonic hedgehog regulates

prostatic growth and epithelial differentiation. Dev Biol 264:

352–362.

Frohlich DA, McCabe MT, Arnold RS, Day ML. 2008. The role

of Nrf2 in increased reactive oxygen species and DNA

damage in prostate tumorigenesis. Oncogene 27: 4353–4362.

Funayama R, Ishikawa F. 2007. Cellular senescence and chromatin structure. Chromosoma 116: 431–440.

Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA,

Finger MJ, Moul JW, Srivastava S. 1994. Frequent detection

of codon 877 mutation in the androgen receptor gene in

advanced prostate cancers. Cancer Res 54: 2861–2864.

Gao J, Arnold JT, Isaacs JT. 2001. Conversion from a paracrine to

an autocrine mechanism of androgen-stimulated growth

during malignant transformation of prostatic epithelial cells.

Cancer Res 61: 5038–5044.

Gao H, Ouyang X, Banach-Petrosky W, Borowsky AD, Lin Y,

Kim M, Lee H, Shih WJ, Cardiff RD, Shen MM, et al. 2004a.




Molecular genetics of prostate cancer




A critical role for p27kip1 gene dosage in a mouse model of

prostate carcinogenesis. Proc Natl Acad Sci 101: 17204–

17209.

Gao, H., Ouyang, X., Banach-Petrosky, W., Borowsky, A.D., Lin,

Y., Kim, M., Lee, H., Shih, W.J., Cardiff, R.D., Shen, M.M.,

et al. 2004b. A critical role for p27kip1 gene dosage in

a mouse model of prostate carcinogenesis. Proc Natl Acad

Sci 101: 17204–17209.

Gao N, Ishii K, Mirosevich J, Kuwajima S, Oppenheimer SR,

Roberts RL, Jiang M, Yu X, Shappell SB, Caprioli RM, et al.

2005. Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development 132: 3431–3443.

Gao H, Ouyang X, Banach-Petrosky WA, Gerald WL, Shen MM,

Abate-Shen C. 2006a. Combinatorial activities of Akt and

B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci 103: 14477–14482.

Gao H, Ouyang X, Banach-Petrosky WA, Shen MM, Abate-Shen

C. 2006b. Emergence of androgen independence at early

stages of prostate cancer progression in nkx3.1; pten mice.

Cancer Res 66: 7929–7933.

Garcia-Echeverria C, Sellers WR. 2008. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27: 5511–5526.

Gelmann EP. 2003. Searching for the gatekeeper oncogene of

prostate cancer. Crit Rev Oncol Hematol 46: S11–S20. doi:

10.1016/S1040-8428(03)00060-X.

Gelmann EP, Steadman DJ, Ma J, Ahronovitz N, Voeller HJ,

Swope S, Abbaszadegan M, Brown KM, Strand K, Hayes RB,

et al. 2002. Occurrence of NKX3.1 C154T polymorphism in

men with and without prostate cancer and studies of its

effect on protein function. Cancer Res 62: 2654–2659.

Gil J, Kerai P, Lleonart M, Bernard D, Cigudosa JC, Peters G,

Carnero A, Beach D. 2005. Immortalization of primary human

prostate epithelial cells by c-Myc. Cancer Res 65: 2179–2185.

Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ,

Greenberg NM. 1997. Androgen-independent prostate cancer

progression in the TRAMP model. Cancer Res 57: 4687–4691.

Gioeli D. 2005. Signal transduction in prostate cancer progression. Clin Sci (Lond) 108: 293–308.

Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr, Weber MJ. 1999.

Activation of mitogen-activated protein kinase associated with

prostate cancer progression. Cancer Res 59: 279–284.

Goldstein AS, Lawson DA, Cheng D, Sun W, Garraway IP, Witte

ON. 2008. Trop2 identifies a subpopulation of murine and

human prostate basal cells with stem cell characteristics.

Proc Natl Acad Sci 105: 20882–20887.

Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON. 2010.

Identification of a cell of origin for human prostate cancer.

Science 329: 568–571.

Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD,

Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen

JM. 1995. Prostate cancer in a transgenic mouse. Proc Natl

Acad Sci 92: 3439–3443.

Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, Mohler

JL, French FS. 1998. Androgen receptor expression in

androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res

58: 5718–5724.

Grignon DJ. 2004. Unusual subtypes of prostate cancer. Mod

Pathol 17: 316–327.

Grisanzio C, Signoretti S. 2008. p63 in prostate biology and

pathology. J Cell Biochem 103: 1354–1368.

Gschwind A, Fischer OM, Ullrich A. 2004. The discovery of

receptor tyrosine kinases: Targets for cancer therapy. Nat

Rev Cancer 4: 361–370.




Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT,

Gudbjartsson D, Helgason A, Rafnar T, Bergthorsson JT,

Agnarsson BA, Baker A, et al. 2007. Genome-wide association study identifies a second prostate cancer susceptibility

variant at 8q24. Nat Genet 39: 631–637.

Gudmundsson J, Sulem P, Gudbjartsson DF, Blondal T, Gylfason

A, Agnarsson BA, Benediktsdottir KR, Magnusdottir DN,

Orlygsdottir G, Jakobsdottir M, et al. 2009. Genome-wide

association and replication studies identify four variants

associated with prostate cancer susceptibility. Nat Genet

41: 1122–1126.

Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen

JH, Mullholland DJ, Magnuson MA, Wu H, Sabatini DM. 2009.

mTOR complex 2 is required for the development of prostate

cancer induced by Pten loss in mice. Cancer Cell 15: 148–159.

Guo Z, Dai B, Jiang T, Xu K, Xie Y, Kim O, Nesheiwat I, Kong X,

Melamed J, Handratta VD, et al. 2006. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer

Cell 10: 309–319.

Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Kong X,

Melamed J, Tepper CG, Kung HJ, et al. 2009. A novel

androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletionresistant growth. Cancer Res 69: 2305–2313.

Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C,

Hicks JL, Morgan J, Cornish TC, Sutcliffe S, et al. 2008.

Nuclear MYC protein overexpression is an early alteration in

human prostate carcinogenesis. Mod Pathol 21: 1156–1167.

Gurel B, Ali TZ, Montgomery EA, Begum S, Hicks J, Goggins M,

Eberhart CG, Clark DP, Bieberich CJ, Epstein JI, et al. 2010.

NKX3.1 as a marker of prostatic origin in metastatic tumors.

Am J Surg Pathol 34: 1097–1105.

Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel

B, Isaacs WB, Bova GS, Liu W, Xu J, et al. 2010. Androgeninduced TOP2B-mediated double-strand breaks and prostate

cancer gene rearrangements. Nat Genet 42: 668–675.

Haggman MJ, Wojno KJ, Pearsall CP, Macoska JA. 1997. Allelic

loss of 8p sequences in prostatic intraepithelial neoplasia and

carcinoma. Urology 50: 643–647.

Haiman CA, Patterson N, Freedman ML, Myers SR, Pike MC,

Waliszewska A, Neubauer J, Tandon A, Schirmer C, McDonald

GJ, et al. 2007. Multiple regions within 8q24 independently

affect risk for prostate cancer. Nat Genet 39: 638–644.

Han G, Buchanan G, Ittmann M, Harris JM, Yu X, Demayo FJ,

Tilley W, Greenberg NM. 2005. Mutation of the androgen

receptor causes oncogenic transformation of the prostate.

Proc Natl Acad Sci 102: 1151–1156.

Hanenszel W, Kurihari M. 1968. Studies of Japanese migrants:

Mortality from cancer and other diseases among Japanese in

the United States. J Natl Cancer Inst 40: 43–68.

Harzstark AL, Small EJ. 2007. Immunotherapy for prostate

cancer using antigen-loaded antigen-presenting cells:

APC8015 (Provenge). Expert Opin Biol Ther 7: 1275–1280.

Haverkamp J, Charbonneau B, Ratliff TL. 2008. Prostate inflammation and its potential impact on prostate cancer: A

current review. J Cell Biochem 103: 1344–1353.

Hayward SW, Wang Y, Cao M, Hom YK, Zhang B, Grossfeld GD,

Sudilovsky D, Cunha GR. 2001. Malignant transformation in

a nontumorigenic human prostatic epithelial cell line. Cancer Res 61: 8135–8142.

He HH, Meyer CA, Shin H, Bailey ST, Wei G, Wang Q, Zhang Y,

Xu K, Ni M, Lupien M, et al. 2010. Nucleosome dynamics

define transcriptional enhancers. Nat Genet 42: 343–347.

Higgins B, Thompson IM. 2004. The prostate cancer prevention

trial: Current status. J Urol 171: S15–S18. doi: 10.1097/

01.ju.0000107440.15626.11.




GENES & DEVELOPMENT




1991




Shen and Abate-Shen




Hill RP. 2006. Identifying cancer stem cells in solid tumors:

Case not proven. Cancer Res 66: 1891–1895.

Hill R, Song Y, Cardiff RD, Van Dyke T. 2005. Heterogeneous

tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model. Cancer Res 65: 10243–10254.

Hill KM, Kalifa S, Das JR, Bhatti T, Gay M, Williams D,

Taliferro-Smith L, De Marzo AM. 2010. The role of PI

3-kinase p110b in AKT signally, cell survival, and proliferation in human prostate cancer cells. Prostate 70: 755–764.

Holcomb IN, Grove DI, Kinnunen M, Friedman CL, Gallaher IS,

Morgan TM, Sather CL, Delrow JJ, Nelson PS, Lange PH,

et al. 2008. Genomic alterations indicate tumor origin and

varied metastatic potential of disseminated cells from prostate cancer patients. Cancer Res 68: 5599–5608.

Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang

L, Ryan C, Smith S, Scher H, Scardino P, et al. 2004. Gene

expression analysis of human prostate carcinoma during

hormonal therapy identifies androgen-responsive genes and

mechanisms of therapy resistance. Am J Pathol 164: 217–227.

Hooker S, Hernandez W, Chen H, Robbins C, Torres JB,

Ahaghotu C, Carpten J, Kittles RA. 2010. Replication of

prostate cancer risk loci on 8q24, 11q13, 17q12, 19q33, and

Xp11 in African Americans. Prostate 70: 270–275.

Horvath LG, Henshall SM, Lee CS, Kench JG, Golovsky D,

Brenner PC, O’Neill GF, Kooner R, Stricker PD, Grygiel JJ,

et al. 2005. Lower levels of nuclear b-catenin predict for

a poorer prognosis in localized prostate cancer. Int J Cancer

113: 415–422.

Hu Y, Dobi A, Sreenath T, Cook C, Tadase AY, Ravindranath L,

Cullen J, Furusato B, Chen Y, Thangapazham RL, et al. 2008.

Delineation of TMPRSS2-ERG splice variants in prostate

cancer. Clin Cancer Res 14: 4719–4725.

Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E,

Han M, Partin AW, Vessella RL, Isaacs WB, et al. 2009.

Ligand-independent androgen receptor variants derived from

splicing of cryptic exons signify hormone-refractory prostate

cancer. Cancer Res 69: 16–22.

Huang L, Pu Y, Hu WY, Birch L, Luccio-Camelo D, Yamaguchi

T, Prins GS. 2009. The role of Wnt5a in prostate gland

development. Dev Biol 328: 188–199.

Hudson DL. 2004. Epithelial stem cells in human prostate growth

and disease. Prostate Cancer Prostatic Dis 7: 188–194.

Huggins C, Hodges CV. 1941. The effect of castration, of

estrogens, and of androgen injection on serum phosphatase

in metastatic carcinoma of prostate. Cancer Res 1: 293–297.

Humphrey PA. 2007. Diagnosis of adenocarcinoma in prostate

needle biopsy tissue. J Clin Pathol 60: 35–42.

Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim RI,

Peltola M, Smit F, Verhaegh G, Schalken J, et al. 2006.

TMPRSS2 fusions with oncogenic ETS factors in prostate

cancer involve unbalanced genomic rearrangements and are

associated with HDAC1 and epigenetic reprogramming.

Cancer Res 66: 10242–10246.

Isaacs JT. 1985. Control of cell proliferation and cell death in the

normal and neoplastic prostate: A stem cell model. In Benign

prostatic hyperplasia (ed. CH Rodgers, et al.), pp. 85–94.

Department of Helath and Human Services, Washington, DC.

Isaacs JT, Coffey DS. 1981. Adaptation versus selection as the

mechanism responsible for the relapse of prostatic cancer to

androgen ablation therapy as studied in the Dunning R-3327-H

adenocarcinoma. Cancer Res 41: 5070–5075.

Ismail HA, Lessard L, Mes-Masson AM, Saad F. 2004. Expression

of NF-kB in prostate cancer lymph node metastases. Prostate

58: 308–313.

Iwata T, Schultz D, Hicks J, Hubbard GK, Mutton LN, Lotan TL,

Bethel C, Lotz MT, Yegnasubramanian S, Nelson WG, et al.




1992




GENES & DEVELOPMENT




2010. MYC overexpression induces prostatic intraepithelial

neoplasia and loss of Nkx3.1 in mouse luminal epithelial

cells. PLoS ONE 5: e9427. doi: 10.1371/journal.pone.0009427.

Jackson RS II, Franco OE, Bhowmick NA. 2008. Gene targeting

to the stroma of the prostate and bone. Differentiation 76:

606–623.

Jenkins RB, Qian J, Lieber MM, Bostwick DG. 1997. Detection

of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ

hybridization. Cancer Res 57: 524–531.

Jeong JH, Wang Z, Guimaraes AS, Ouyang X, Figueiredo JL, Ding

Z, Jiang S, Guney I, Kang GH, Shin E, et al. 2008. BRAF

activation initiates but does not maintain invasive prostate

adenocarcinoma. PLoS ONE 3: e3949. doi: 10.1371/journal.

pone.0003949.

Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti

S, Loda M, Roberts TM, et al. 2008. Essential roles of PI(3)Kp110b in cell growth, metabolism and tumorigenesis. Nature

454: 776–779.

Jia L, Landan G, Pomerantz M, Jaschek R, Herman P, Reich D,

Yan C, Khalid O, Kantoff P, Oh W, et al. 2009. Functional

enhancers at the gene-poor 8q24 cancer-linked locus. PLoS

Genet 5: e1000597. doi: 10.1371/journal.pgen.1000597.

Jiang Z, Li C, Fischer A, Dresser K, Woda BA. 2005. Using an

AMACR (P504S)/34bE12/p63 cocktail for the detection of

small focal prostate carcinoma in needle biopsy specimens.

Am J Clin Pathol 123: 231–236.

Jiang M, Strand DW, Fernandez S, He Y, Yi Y, Birbach A, Qiu Q,

Schmid J, Tang DG, Hayward SW. 2010. Functional remodeling of benign human prostatic tissues in vivo by spontaneously immortalized progenitor and intermediate cells.

Stem Cells 28: 344–356.

Jiao J, Wang S, Qiao R, Vivanco I, Watson PA, Sawyers CL, Wu

H. 2007. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res 67: 6083–

